Milestone Pharmaceuticals Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) resulting from allegations that Milestone may have issued materially misleading business information to the investing public.

If you purchased Milestone securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Milestone securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On December 26, 2023, before the market opened, Milestone Pharmaceuticals, Inc. announced that it had received a Refuse to File (“RTF”) letter from the U.S. Food and Drug Administration (“FDA”) for its recently submitted new drug application for its lead investigational product, Etripamil, a self-administered nasal spray for the treatment of paroxysmal supraventricular tachycardia. In the RTF, the FDA noted that Milestone had not provided the agency with sufficient information to permit substantive review, and sought additional information related to the timing of adverse events in Etripamil’s Phase 3 trial.

On this news, Milestone’s stock fell $0.89 per share, or 30.90%, to close at $1.99 per share on December 26, 2023.

公司名称: Milestone Pharmaceuticals Inc.
股票代号: MIST
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。